- $194.24m
- -$14.48m
- $134.48m
Rxsight Inc reports results for the quarter - Earnings Summary
Brief: Rxsight Q3 Revenue USD 35.3 Million Vs. IBES Estimate USD 35.1 Million
Rxsight Inc reports results for the quarter ended in June - Earnings Summary
Brief: Rxsight Q2 Revenue USD 34.9 Million Vs. IBES Estimate USD 32.3 Million
U.S. STOCKS ON THE MOVE-Gold miners, Energy Transfer, Aercap
RxSight falls on pricing $100 mln stock offering
Brief: Rxsight Announces Pricing Of Public Offering Of Common Stock
Brief: Rxsight Inc Files For Mixed Shelf Size Not Disclosed - SEC Filing
Brief: Rxsight Q1 Revenue USD 29.5 Million Vs. IBES Estimate USD 27.6 Million
Rxsight Inc expected to post a loss of 27 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Okta, Salesforce, Sarepta Therapeutics
Rxsight Inc reports results for the quarter ended in December - Earnings Summary
Brief: Rxsight Q4 Gross Profit USD 17.7 Million
Rxsight Inc expected to post a loss of 36 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Ball, Couchbase, Holley
RxSight gains as brokerages lift PT on upbeat prelim 2024 revenue forecast
Brief: RxSight Says Anticipates FY 2024 Revenue Of $128 Mln-$135 Mln, Reflecting Growth Of About 44%-52% Over 2023
Brief: Rxsight Q4 Revenue USD 28.6 Million Vs. IBES Estimate USD 25.8 Million
Brief: Rxsight Q3 Revenue USD 22.2 Million Vs. IBES Estimate USD 20.6 Million